[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"postoperative-nausea-and-vomiting\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:postoperative-nausea-and-vomiting":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,20,0,[8,45,75,103,128,158,184,212,240,261,286,317,341,369,390,413,430,454,482,501],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100643322","phase-4-time-to-first-rescue-antiemetic-with-ondansetron-plus-metoclopramide-versus-dexamethasone-plus-metoclopramide-for-ponv-prophylaxis-in-laparoscopic-cholecystectomy-100643322",false,"NCT07638527","Time to First Rescue Antiemetic With Ondansetron Plus Metoclopramide Versus Dexamethasone Plus Metoclopramide for PONV Prophylaxis in Laparoscopic Cholecystectomy","Time-to-first-rescue Antiemetic With Ondansetron Plus Metoclopramide Versus Dexamethasone Plus Metoclopramide for PONV Prophylaxis in Laparoscopic Cholecystectomy: a Randomized, Triple-Blind, Superiority Trial","Inclusion Criteria:\n\n* Age ≥ 18 years\n* American Society of Anesthesiologists (ASA) physical status I or II\n* Scheduled for elective laparoscopic cholecystectomy\n* Apfel score 2-4 (moderate to high risk for PONV)\n* Provides written informed consent prior to enrollment\n\nExclusion Criteria:\n\n* Known allergy or hypersensitivity to ondansetron, dexamethasone, or metoclopramide\n* Emergency surgery (e.g., acute cholecystitis, perforation, or gangrene)\n* Pregnancy or breastfeeding\n* ASA physical status III or IV\n* Preexisting hepatic impairment\n* Baseline corrected QT (QTc) interval \\> 420 ms on pre-operative ECG\n* History of dystonic reaction to metoclopramide or other dopamine antagonists\n* Preexisting renal impairment (e.g., serum creatinine \\> 1.5 mg\u002FdL or on dialysis)\n* Unable or unwilling to provide informed consent","ALL","18 Years",{"count":19,"type":20},264,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","The goal of this superiority randomized controlled trial (RCT) is to learn if one dual-drug arm increases patient comfort (time to needing rescue medication for nausea\u002Fvomiting) more effectively than the other in adults with Moderate-to-High PONV risk (Apfel score 2-4) undergoing elective laparoscopic cholecystectomy (gallbladder surgery).\n\nThe main question this study aims to answer is:\n\n• Does Ondansetron plus Metoclopramide prolong time to first rescue antiemetic more than Dexamethasone plus Metoclopramide?\n\nResearchers will compare Group A (Ondansetron 4mg plus Metoclopramide 10mg IV) to Group B (Dexamethasone 8mg IV plus Metoclopramide 10mg IV) to see if Group A provides a longer time to first rescue medication.\n\nParticipants will:\n\n* Receive their assigned, blinded drug group 5-10 minutes before general anesthesia induction.\n* Receive rescue Metoclopramide 10mg IV if they experience any vomiting or severe nausea\n* Be monitored for 24 hours post-surgery in the hospital\n* Report nausea severity at 2, 6, 12 and 24 hours post-surgery",[26],"Postoperative Nausea and Vomiting",[28,29,30,31],"PONV","Postoperative emesis","Postoperative nausea","Postoperative vomiting","NOT_YET_RECRUITING","2026-06-09",{"date":35,"type":36},"2026-06-11","ACTUAL",{"date":38,"type":20},"2026-07",{"date":40,"type":20},"2027-04",{"name":42,"class":43},"Faisalabad Medical University","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":44},"100597860","use-of-transcutaneous-electrical-nerve-stimulation-device-reletex-reliefband-with-current-eras-enhanced-recovery-after-surgery-protocol-to-further-decrease-postoperative-nausea-and-vomiting-in-the-bariatric-surgical-patient-within-the-first-24-hours-postoperatively-100597860","NCT07063979","Use of Transcutaneous Electrical Nerve Stimulation Device, Reletex Reliefband, With Current ERAS (Enhanced Recovery After Surgery) Protocol to Further Decrease Postoperative Nausea and Vomiting in the Bariatric Surgical Patient Within the First 24 Hours Postoperatively.","Use of Transcutaneous Electrical Nerve Stimulation Device, Reletex Reliefband to Decrease Postoperative Nausea and Vomiting in the Bariatric Surgical Patient","Inclusion Criteria:\n\n* Adults 18-75 years of age\n* BMI 35 or greater\n* Patients eligible for and undergoing a Robotic Sleeve Gastrectomy\n* Able to consent on own behalf\n\nExclusion Criteria:\n\n* A diagnosis of gastroparesis\n* Pregnancy\n* Presence of a cardiac pacemaker\u002Fdefibrillator or intrathecal pump\n* Current smoker or tobacco use within 30 days of procedure.\n* Known allergic reactions to conductivity gel.\n\nDue to the nature of the Robotic Sleeve Gastrectomy patients who may be unable to follow or comprehend the long-term restrictions and\u002For requirements inherent of the surgery due to altered mentation are excluded from having the surgery.","75 Years",{"count":54,"type":20},100,[56],"NA","The goal of this clinical trial is to learn if the Reletex Reliefband device when used in conjunction with our current treatments will further decrease postoperative nausea and vomiting. The Investigators want to test how well it works, specifically in bariatric surgery patients that are at a higher risk for nausea and vomiting after surgery. Furthermore, the investigators would like to see if using this non-drug treatment option might allow for the same or better control of nausea and vomiting with fewer side effects than the current medications used. This may decrease drowsiness, and allow for earlier mobility, increase comfort, and generally accelerate recovery after surgery.\n\nThe main questions it aims to answer are:\n\n* Does the use of Reletex Reliefband decrease postoperative nausea and vomiting (PONV) in the Bariatric surgical patient, therefore decreasing need for additional anti-emetics.\n* Does the use of Reletex Reliefband the use of the Reletex Reliefband during the immediate post-operative period reduce PONV, allowing for early mobility, decreased pain and length of stay (LOS).\n* Does the use of Reletex Reliefband decrease the use of medications for nausea and therefore decrease costs.\n* Does the use of Reletex Reliefband reduce prolonged PONV and therefore prevent the downstream effects, i.e. less mobility, increased pain, inhibit the patients' ability to comply with recommended treatments.\n* If reducing PONV using non-pharmaceutical approaches will improve outcomes and patient experiences.\n\nResearchers will compare to a placebo (a look-alike device) to see if the Reletex Reliefband works to decrease PONV.\n\nParticipants will:\n\n* All receive the standard Enhanced Recovery After Surgery (ERAS) Protocol before, during and after surgery. (This includes use of premedications for pain, and nausea)\n* Have a band applied and turned on at the completion of the patient's bariatric sleeve surgery. The band will be adjusted based on need and worn for a total of 24 hours postoperatively.\n* Have a pedometer clipped to their gown, to remain in place for 24 hours postoperatively\n* Be assessed regularly during their hospital stay by the nurses to monitor the site of the band, their level of nausea\u002Fvomiting, pain levels, and level of mobility",[26,59],"Bariatric Sleeve Gastrectomy",[61,62,63,64],"Prevention of Postoperative Nausea and Vomiting in Bariatric Patient","Reletex Reliefband to prevent PONV","Preventing PONV in Bariartic Postop patient","Reliefband","RECRUITING","2026-06-08",{"date":68,"type":36},"2026-06-10",{"date":70,"type":36},"2025-11-04",{"date":72,"type":20},"2027-07",{"name":74,"class":43},"University of Pennsylvania",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":82,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":21,"phases":86,"briefSummary":87,"conditions":88,"keywords":92,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":4},"100643545","the-use-of-a-comfort-tote-to-improve-recovery-in-pediatric-and-adolescent-patients-after-surgery-100643545","NCT07632833","The Use of a Comfort Tote to Improve Recovery in Pediatric and Adolescent Patients After Surgery","The Use of the Comfort Tote Following Posterior Spinal Fusion for Adolescent Idiopathic Scoliosis: a Randomized Controlled Trial Pilot Study","Inclusion Criteria:\n\n* Patients of all genders, racial, and ethnic groups aged between 10 and 21 that have had been diagnosed with AIS requiring surgical correction with PSF.\n* Patients must be scheduled to undergo PSF at Morgan Stanley Children's Hospital of NYP.\n* The patients and their parent(s)\u002Flegal guardian(s) must also provide informed consent, for those under 18 years old.\n* The patient population will include mental health conditions such as anxiety and\u002For depression and all surgery levels.\n\nExclusion Criteria:\n\n* Patients who have had growing rods and revisions, those who have local or systemic infections, those with anemia, cardiovascular diseases, or osteoporosis, and patients with severe medical comorbidities such as neurological or developmental condition that precludes engagement with the Comfort Tote\n* Patients with two or more chronic conditions (excluding AIS)","12 Years","21 Years",{"count":85,"type":20},50,[56],"The goal of this clinical trial is to learn if the use of Comfort Tote can treat pain and anxiety in adolescents with idiopathic scoliosis undergoing posterior spinal fusion. The study aims to answer two questions:\n\n1. To characterize the effectiveness and determine the impact of integrative therapy interventions of the Comfort Tote use in reducing self-reported pain, anxiety, and stress among pediatric patients with AIS undergoing PSF. By comparing self-reported pain, anxiety, and stress scores, as well as documented Morphine Milligram Equivalents (MMEs) and Numeric Rating Scale (NRS) pain scores, between patients using non-therapeutic and therapeutic Comfort Totes.\n2. To evaluate the impact of an educational video on the use of the Comfort Tote. This will assess whether the inclusion of instructional content enhances understanding and application of the Comfort Tote, thereby improving patient outcomes in pain management, anxiety reduction, and overall satisfaction with care. It is hypothesized that the therapeutic Comfort Tote intervention with the educational video will provide the highest patient satisfaction and greater tote usage, with decreased patient pain, stress, and anxiety levels. The findings from this pilot study will provide crucial insights into establishing a new standard of care for pediatric patients undergoing PSF and potentially provide baseline data for use in larger, multicenter randomized controlled trials.",[89,90,26,91],"Adolescent Idiopathic Scoliosis","Postoperative Pain, Acute","Anxiety",[93,94],"Posterior spinal fusion","Integrative therapy","2026-06-02",{"date":66,"type":36},{"date":98,"type":20},"2026-06-15",{"date":100,"type":20},"2028-06-30",{"name":102,"class":43},"Columbia University",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":21,"phases":113,"briefSummary":114,"conditions":115,"keywords":117,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":44},"100607587","phase-4-ginger-to-prevent-nausea-and-vomiting-after-laparoscopic-cholecystectomy-100607587","NCT07190495","Ginger to Prevent Nausea and Vomiting After Laparoscopic Cholecystectomy","Preoperative Ginger for the Prevention of Postoperative Nausea and Vomiting in Patients Undergoing Laparoscopic Cholecystectomy: A Double-Blind Randomized Controlled Trial","GINGER-PONV","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Scheduled for elective laparoscopic cholecystectomy under general anesthesia.\n* American Society of Anesthesiologists (ASA) physical status I-III.\n* Able to understand the study procedures and provide written informed consent.\n\nExclusion Criteria:\n\n* Known allergy or hypersensitivity to ginger\n* Documented history of bleeding disorders or current treatment with anticoagulant agents\n* History of severe postoperative nausea and vomiting or an Apfel score of 4\n* Administration of antiemetic drugs or corticosteroids during the preoperative period\n* Pregnancy or breastfeeding\n* Active gastrointestinal or liver disease",{"count":112,"type":20},102,[23],"This study aims to evaluate whether preoperative oral administration of ginger (800 mg, given 2 hours before surgery) reduces the incidence and severity of postoperative nausea and vomiting (PONV) within the first 24 hours after laparoscopic cholecystectomy.",[26,116],"Laparoscopic Cholecystectomy",[118,26,116],"Ginger","2026-04-27",{"date":121,"type":36},"2026-04-28",{"date":123,"type":36},"2025-07-05",{"date":125,"type":20},"2026-12",{"name":127,"class":43},"University Tunis El Manar",{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":135,"minAge":17,"maxAge":136,"enrollmentInfo":137,"targetDuration":4,"studyType":139,"phases":4,"briefSummary":140,"conditions":141,"keywords":144,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":154,"leadSponsor":156,"locationsCount":44},"100634449","effects-of-menstrual-cycle-on-optic-nerve-sheath-diameter-in-patients-undergoing-laparoscopic-gynecologic-surgery-100634449","NCT07539831","Effects of Menstrual Cycle on Optic Nerve Sheath Diameter in Patients Undergoing Laparoscopic Gynecologic Surgery","The Effect of Menstrual Cycle Phase on Optic Nerve Sheath Diameter in Patients Undergoing Laparoscopic Gynecologic Surgery","Inclusion Criteria:\n\n* Female patients aged 18 to 45 years\n* Scheduled for elective laparoscopic gynecologic surgery\n* Menstrual cycle in the follicular phase or luteal phase\n* American Society of Anesthesiologists (ASA) physical status I-II\n\nExclusion Criteria:\n\n* Irregular menstrual cycle (e.g., polycystic ovary syndrome, early menopause, hypothalamic amenorrhea)\n* Pregnancy or breastfeeding\n* Neurological disease associated with intracranial pressure changes\n* Glaucoma or another eye disease associated with high intraocular pressure\n* Previous brain surgery\n* Uncontrolled hypertension or severe cardiovascular disease","FEMALE","45 Years",{"count":138,"type":20},110,"OBSERVATIONAL","This observational study aims to evaluate the effect of menstrual cycle phase on optic nerve sheath diameter (ONSD) in women undergoing elective laparoscopic gynecologic surgery. Patients will be grouped according to menstrual cycle phase as follicular or luteal. ONSD measurements will be performed perioperatively, and postoperative nausea and vomiting as well as postoperative cognitive function will also be assessed. The study is designed to investigate whether hormonal variations during the menstrual cycle are associated with differences in intracranial pressure reflected by ONSD measurements and postoperative outcomes",[142,143,26],"Menstrual Cycle","Optic Nerve Sheath Diameter",[143,145,146,147,148,149],"Laparoscopic Gynecologic Surgery","Mini-Mental State Examination","Verbal Descriptive Scale","Follicular Phase","Luteal Phase","2026-04-20",{"date":152,"type":36},"2026-04-21",{"date":150,"type":36},{"date":155,"type":20},"2027-04-05",{"name":157,"class":43},"Konya City Hospital",{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":4,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":165,"enrollmentInfo":166,"targetDuration":4,"studyType":21,"phases":168,"briefSummary":169,"conditions":170,"keywords":174,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":177,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":44},"100635439","usg-guided-tapa-vs-rifb-block-for-postoperative-analgesia-in-laparoscopic-cholecystectomy-100635439","NCT07552701","USG-Guided TAPA vs RIFB Block for Postoperative Analgesia in Laparoscopic Cholecystectomy","Comparison of Ultrasonography-Guided the Postoperative Analgesic Efficacy of Perichondrial Approach Modified Thoracoabdominal Nerve Block and Recto-Intercostal Fascial Plan Block in Patients Who Underwent Laparoscopic Cholecystectomy","Inclusion Criteria:\n\n* Age 18-65 years\n* ASA physical classification I-II\n* BMI \\\u003C 35 kg\u002Fm²\n* Scheduled for elective laparoscopic cholecystectomy due to cholelithiasis\n* Able to use and understand the NRS pain scoring system\n* Able to use and understand the QoR-15 scale\n* Able to communicate in Turkish\n* Provided written informed consent\n\nExclusion Criteria:\n\n* Refusal to participate in the study\n* BMI \\> 35 kg\u002Fm²\n* ASA physical classification III-V\n* Age \\\u003C 18 or \\> 65 years\n* Allergy to local anesthetics or study analgesics\n* Pregnancy or breastfeeding\n* Inability to use or understand the NRS pain scoring system or QoR-15 scale\n* Inability to communicate in Turkish\n* Uncontrolled anxiety disorder\n* Alcohol or drug dependency\n* Neuromuscular or peripheral nerve disease\n* High-dose opioid use within 3 days prior to surgery\n* Widespread chronic pain\n* Diabetes mellitus\n* Hepatic or renal insufficiency\n* Coagulation disorders or anticoagulant use\n* Infection at the block needle insertion site\n* Concurrent second surgical procedure alongside laparoscopic cholecystectomy\n* Previous abdominal surgery or trauma history\n* Conversion from laparoscopic to open surgery\n* Technical problems with the PCA device\n* NRS score \\> 7 for four consecutive hours despite multimodal analgesia\n* Planned postoperative non-extubation\n* Termination of surgery before completion for any reason","65 Years",{"count":167,"type":20},70,[56],"Laparoscopic cholecystectomy (LC) can cause moderate-to-severe postoperative pain from visceral, referred shoulder, and incisional sources. Multimodal analgesia is recommended, but opioids carry significant side effects. Ultrasound-guided interfascial plane blocks offer a safe alternative. The Modified Thoracoabdominal Nerve Block through Perichondrial Approach (M-TAPA) blocks T5-T12 dermatomes, while the Recto-Intercostal Fascial Plane Block (RIFPB) provides sensory blockade across the upper anterolateral abdomen. This study compares the postoperative analgesic efficacy of bilateral M-TAPA versus bilateral RIFPB in patients undergoing LC.",[171,172,173,26],"Postoperative Pain","Acute Cholecystitis","Cholelithiasis",[116,175,176],"Transversus abdominis Plane Block","Rectus-intercostalis facial plane block",{"date":119,"type":36},{"date":179,"type":36},"2025-03-16",{"date":181,"type":20},"2026-05-30",{"name":183,"class":43},"Hitit University",{"id":185,"slug":186,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":4,"eligibilityCriteria":190,"healthyVolunteers":11,"sex":135,"minAge":17,"maxAge":191,"enrollmentInfo":192,"targetDuration":194,"studyType":139,"phases":4,"briefSummary":195,"conditions":196,"keywords":197,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":44},"100611563","sugammadex-and-menstrual-cycle-in-postoperative-nausea-and-vomiting-100611563","NCT07242209","Sugammadex and Menstrual Cycle in Postoperative Nausea and Vomiting","The Relationship Between Menstrual Cycle Phases and Postoperative Nausea and Vomiting: The Role of Sugammadex","Inclusion Criteria:\n\n* Female sex\n* Age between 18 and 40 years\n* Regular menstrual cycle\n* Scheduled for ENT (ear, nose, and throat) surgery\n* Classified as ASA physical status I or II\n\nExclusion Criteria:\n\n* Irregular menstrual cycle\n* Unknown date of last menstrual period\n* Receiving estrogen and\u002For progesterone supplementation\n* Pre-menopausal or menopausal status\n* Pregnant\n* Breastfeeding\n* Classified as ASA physical status III or IV\n* Apfel score ≥ 3\n* History of drug allergy\n* Surgery duration exceeding 3 hours\n* Age \\\u003C18 or \\>40 years","40 Years",{"count":193,"type":20},60,"3 Days","This observational study aims to evaluate the relationship between menstrual cycle phases and the incidence of postoperative nausea and vomiting (PONV) in women of reproductive age undergoing septorhinoplasty surgery. The study's primary objective is to determine whether different phases of the menstrual cycle are associated with variations in PONV frequency. As a secondary objective, the relationship between menstrual phases, PONV incidence, and the use of sugammadex during anesthesia will be analyzed. No additional intervention will be applied beyond routine clinical practice; all data will be collected prospectively from anesthesia records and postoperative evaluations.",[26,142],[198,199,200,201,202],"postoperative nausea and vomiting","menstruel cycle","septorhinoplasty","sugammadex","female reproductive age","2026-03-09",{"date":205,"type":36},"2026-03-10",{"date":207,"type":36},"2025-12-18",{"date":209,"type":20},"2026-05-15",{"name":211,"class":43},"Sakarya University",{"id":213,"slug":214,"hasResults":11,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":4,"eligibilityCriteria":218,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":219,"targetDuration":4,"studyType":21,"phases":220,"briefSummary":221,"conditions":222,"keywords":225,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":4},"100627650","intraoperative-pyloric-balloon-dilatation-to-reduce-delayed-gastric-emptying-after-pppd-100627650","NCT07451392","Intraoperative Pyloric Balloon Dilatation to Reduce Delayed Gastric Emptying After PPPD","Intraoperative Pyloric Balloon Dilatation to Decrease Post PPPD Delayed Gastric Emptying. Does It Help? RCT Study","Inclusion Criteria:\n\n* Adult patients (≥18 years) scheduled for elective PPPD due to tumors of the pancreatic head, distal bile duct, or ampulla of Vater.\n* Patients with no prior history of gastric surgery or severe gastroparesis.\n* Patients with no contraindications to balloon dilatation or intraoperative endoscopic procedures\n\nExclusion Criteria:\n\n* Patients with prior gastric surgery, pyloric stenosis, or history of severe gastroparesis.\n* Patients with severe comorbidities that may preclude safe surgery (ASA class IV or higher).\n* Patients who require emergency surgery or have unresectable disease.\n* Patients with active gastrointestinal bleeding or severe malnutrition",{"count":167,"type":20},[56],"Pylorus-preserving pancreatoduodenectomy (PPPD) is a standard surgical treatment for tumors of the pancreatic head and surrounding areas. However, it is frequently associated with delayed gastric emptying (DGE), a complication that can lead to nausea, vomiting, and prolonged hospital stays. This study is a randomized controlled trial designed to evaluate if a simple intraoperative maneuver (pneumatic balloon dilatation of the pylorus) can reduce the incidence of early postoperative vomiting and DGE.\n\nParticipants will be randomly assigned to either the intervention group, receiving pyloric dilatation during surgery, or the control group, receiving standard surgery without dilatation. Researchers will monitor postoperative symptoms, gastric emptying function, and overall recovery to determine if this maneuver effectively improves patient outcomes.",[223,26,224],"Delayed Gastric Emptying","Gastric Emptying Time",[223,226,227,228,229,230],"Pylorus-Preserving Pancreatoduodenectomy","PPPD","Pyloric Balloon Dilatation","Early Postoperative Vomiting","Pylorospasm","2026-02-28",{"date":233,"type":36},"2026-03-05",{"date":235,"type":20},"2026-04",{"date":237,"type":20},"2027-05",{"name":239,"class":43},"Assiut University",{"id":241,"slug":242,"hasResults":11,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":246,"eligibilityCriteria":247,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":248,"targetDuration":4,"studyType":139,"phases":4,"briefSummary":250,"conditions":251,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":259,"locationsCount":44},"100611745","association-between-preoperative-metformin-exposure-and-postoperative-nausea-and-vomiting-in-patients-undergoing-general-anesthesia-100611745","NCT07244575","Association Between Preoperative Metformin Exposure and Postoperative Nausea and Vomiting in Patients Undergoing General Anesthesia","Association Between Preoperative Metformin Exposure and Postoperative Nausea and Vomiting in Patients Undergoing General Anesthesia: a Prospective Observational Cohort Study","Met-PONV","Inclusion criteria\n\n1. Voluntarily sign the informed consent form;\n2. Age ≥ 18 years;\n3. Patients who require surgical treatment under endotracheal intubation with general anesthesia as determined by the treating physician.\n\nExclusion criteria\n\n1. Emergency surgery;\n2. Currently taking medications with established antiemetic effects (e.g., corticosteroids, antipsychotics) due to underlying medical conditions;\n3. Cognitive impairment or psychiatric disorders that preclude cooperation with questionnaire assessments;\n4. Anticipated inability to extubate the tracheal tube postoperatively, which would interfere with outcome assessment;\n5. Presence of nausea and\u002For vomiting prior to surgery.",{"count":249,"type":20},909,"The aim of this observational study is to investigate the potential effects of metformin on postoperative nausea and vomiting (PONV) in patients undergoing surgery under general anesthesia. The primary research question is:\n\nDoes preoperative metformin exposure influence the incidence or severity of PONV in patients undergoing general anesthesia? Patients who are already prescribed metformin as part of their routine medical management will be compared with those not taking metformin. Data on PONV occurrence, severity, and recovery outcomes will be collected through structured postoperative surveys administered after surgery.",[26],"2026-02-05",{"date":254,"type":36},"2026-02-09",{"date":256,"type":36},"2025-12-01",{"date":258,"type":20},"2033-12-31",{"name":260,"class":43},"Sixth Affiliated Hospital, Sun Yat-sen University",{"id":262,"slug":263,"hasResults":11,"nctId":264,"briefTitle":265,"officialTitle":266,"acronym":267,"eligibilityCriteria":268,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":269,"targetDuration":270,"studyType":139,"phases":4,"briefSummary":271,"conditions":272,"keywords":274,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":278,"startDateStruct":280,"completionDateStruct":282,"leadSponsor":284,"locationsCount":44},"100622650","propofol-infusion-and-ponv-in-cardiac-surgery-100622650","NCT07386379","Propofol Infusion and PONV in Cardiac Surgery","The Effect of Propofol Infusion on Postoperative Nausea and Vomiting in Cardiac Surgery: A Prospective Observational Cohort Study","nausea vomitng","Inclusion Criteria\n\nAge ≥ 18 years\n\nASA physical status III\n\nElective coronary artery bypass grafting (CABG)\n\nSurgery performed at Istanbul University-Cerrahpaşa, Cardiology Institute between November 2025 and March 2026\n\nExclusion Criteria\n\nGastrointestinal or central nervous system disorders within the past 3 months\n\nCochlear disorders associated with nausea and vomiting\n\nChronic opioid use\n\nAdvanced hepatic or renal disease\n\nAlcohol or substance abuse\n\nLeft ventricular ejection fraction \\\u003C 40%\n\nInability to be weaned from mechanical ventilation within 12 hours postoperatively\n\nPostoperative morphine administration in the intensive care unit\n\nCombined cardiac procedures (e.g., valve surgery)\n\nOff-pump surgery\n\nEmergency surgery\n\nReoperation due to bleeding or other complications\n\nRefusal to participate",{"count":193,"type":20},"1 Day","The aim of this observational cohort study is to evaluate the effect of high-dose versus low-dose propofol infusion on the incidence of postoperative nausea and vomiting (PONV) in patients undergoing coronary artery bypass grafting (CABG). The study also seeks to assess the predictive performance of the Apfel and Koivuranta risk scores for PONV in the cardiac surgery population.\n\nThe primary objective of this study is to determine the impact of routinely administered high-dose propofol on the incidence and severity of PONV in CABG patients.\n\nThe secondary objective is to evaluate the need for antiemetic therapy during the intensive care unit stay.\n\nThe investigators will compare patients receiving high-dose propofol with those receiving low-dose propofol to determine whether the antiemetic effect of propofol is dose-dependent.\n\nParticipants will be asked to:\n\nAllow PONV assessments to be performed during the first 24 hours postoperatively,\n\nProvide permission for the collection of clinical data (including demographic characteristics, risk scores, opioid consumption, etc.) for research purposes.",[26,273],"Cardiovascular Surgical Procedures",[26,275,276,273],"Propofol","Cardiac Surgical Procedures","2026-02-03",{"date":279,"type":36},"2026-02-04",{"date":281,"type":36},"2025-11-01",{"date":283,"type":20},"2026-04-30",{"name":285,"class":43},"Istanbul University - Cerrahpasa",{"id":287,"slug":288,"hasResults":11,"nctId":289,"briefTitle":290,"officialTitle":291,"acronym":4,"eligibilityCriteria":292,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":293,"targetDuration":4,"studyType":21,"phases":295,"briefSummary":296,"conditions":297,"keywords":299,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":309,"startDateStruct":311,"completionDateStruct":313,"leadSponsor":315,"locationsCount":44},"100618787","eras-based-preoperative-nutrition-and-fasting-in-total-knee-arthroplasty-100618787","NCT07336160","ERAS-Based Preoperative Nutrition and Fasting in Total Knee Arthroplasty","Effect of ERAS-Based Preoperative Nutrition Education and Fasting Protocol on Postoperative Hydration Status and Nausea-Vomiting in Patients Undergoing Total Knee Arthroplasty","Inclusion Criteria:\n\n* Inclusion Criteria:\n* Adults aged 18 years and older.\n* Patients scheduled for elective total knee arthroplasty.\n* Patients expected to be hospitalized for at least 48 hours postoperatively.\n* Ability to communicate verbally and provide informed consent.\n* Patients with adequate cognitive and neurological capacity to understand study procedures.\n\nExclusion Criteria:\n\n* Presence of any chronic disease requiring fluid restriction.\n* Diagnosed cognitive impairment or psychiatric disorders affecting comprehension (e.g., Alzheimer's disease, dementia, psychotic disorders).\n* Acute conditions causing dehydration in the preoperative period (e.g., vomiting, diarrhea, excessive fluid loss).\n* Intraoperative complications requiring intensive care unit admission.\n* Postoperative follow-up shorter than 48 hours due to early discharge or transfer to another clinic.",{"count":294,"type":20},72,[56],"The aim of this randomized controlled study is to investigate the effect of implementing a preoperative nutrition education and fasting protocol prepared in accordance with Enhanced Recovery After Surgery (ERAS) guidelines during the 24-hour preoperative period on postoperative hydration status and the incidence of nausea and vomiting in patients scheduled for total knee arthroplasty.\n\nTotal knee arthroplasty is a commonly performed surgical procedure, particularly in older adults, and postoperative recovery may be negatively affected by surgical stress, anesthesia-related complications, dehydration, and postoperative nausea and vomiting. ERAS protocols emphasize the optimization of preoperative nutrition and hydration as key components to improve postoperative outcomes.\n\nIn this study, patients undergoing elective total knee arthroplasty will be randomly assigned to an intervention group or a control group. Patients in the intervention group will receive ERAS-based preoperative nutrition education and a standardized fasting protocol during the 24 hours prior to surgery, while patients in the control group will receive routine standard care.\n\nPostoperative hydration status, nausea and vomiting severity, and fluid intake-output balance will be assessed and compared between the two groups. The findings of this study are expected to contribute to improving perioperative nursing care practices and enhancing patient recovery and comfort following total knee arthroplasty.",[298,26],"Total Knee Arthroplasty",[300,301,302,303,304,305,306,307],"Enhanced Recovery After Surgery","ERAS Protocol","Preoperative Nutrition","Fasting Protocol","Total Knee Replacement","Postoperative Hydration","Nausea and Vomiting","Perioperative Nursing Care","2026-01-13",{"date":310,"type":36},"2026-01-14",{"date":312,"type":36},"2025-12-26",{"date":314,"type":20},"2026-09-01",{"name":316,"class":43},"Nermin Ocaktan",{"id":318,"slug":319,"hasResults":11,"nctId":320,"briefTitle":321,"officialTitle":322,"acronym":323,"eligibilityCriteria":324,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":325,"targetDuration":4,"studyType":21,"phases":327,"briefSummary":328,"conditions":329,"keywords":331,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":333,"lastUpdatePostDateStruct":334,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":339,"locationsCount":44},"100614614","aromatherapy-in-reducing-ponv-for-total-joint-replacement-patients-100614614","NCT07281885","Aromatherapy in Reducing PONV for Total Joint Replacement Patients","A Randomized Control Trial on the Efficacy of Aromatherapy in Reducing Postoperative Nausea and Vomiting in Total Joint Replacement Patients","RCT PONV","Inclusion Criteria:\n\n* Adults aged 18 or above\n* Patients scheduled for total joint replacement surgery at the HKBH\n\nExclusion Criteria:\n\n* Cognitive impairments\n* Allergy to lavender, orange, ginger, or sandalwood\n* Allergy to micro-pore tape\n* Allergy to opioid medication\n* Undergoing other therapeutic treatment for PONV control, except prescribed medications",{"count":326,"type":20},159,[56],"This study investigates the effectiveness of aromatherapy in reducing postoperative nausea and vomiting (PONV) among patients undergoing total joint replacement surgery, as these complications can lead to patient discomfort and prolonged recovery. It is designed as a randomized controlled trial involving 159 participants, who will be divided into three groups: an intervention group receiving aromatherapy patches (lavender-sandalwood or orange-ginger) plus standard care, a placebo group with a placebo patch plus standard care, and a control group receiving standard care alone. PONV will be measured using the Rhodes Index of Nausea, Vomiting, and Retching (RINVR) at baseline, 30 minutes after the intervention, and every 12 hours post-surgery. Additionally, patient satisfaction will be assessed through a 5-point Likert scale survey. The primary outcome of the study is the evaluation of RINVR scores, while the secondary outcome focuses on patient satisfaction levels. Data will be statistically analyzed using two-way ANOVA for repeated measures, with a significance level defined as p \\\u003C 0.05. The study aims to determine the viability of aromatherapy as a complementary treatment for PONV, potentially improving postoperative care, enhancing patient satisfaction, and offering a cost-effective alternative to conventional anti emetic treatments if proven effective.",[330,26],"Total Joint Replacement Surgery",[332,28],"Aromatherapy","2026-01-05",{"date":335,"type":36},"2026-01-07",{"date":337,"type":36},"2025-09-01",{"date":125,"type":20},{"name":340,"class":43},"Hong Kong Buddhist Hospital",{"id":342,"slug":343,"hasResults":11,"nctId":344,"briefTitle":345,"officialTitle":346,"acronym":347,"eligibilityCriteria":348,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":165,"enrollmentInfo":349,"targetDuration":4,"studyType":21,"phases":351,"briefSummary":352,"conditions":353,"keywords":355,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":360,"lastUpdatePostDateStruct":361,"startDateStruct":362,"completionDateStruct":364,"leadSponsor":366,"locationsCount":44},"100614024","paragastric-block-for-pain-and-ponv-in-sleeve-gastrectomy-100614024","NCT07274215","Paragastric Block for Pain and PONV in Sleeve Gastrectomy","Impact of Intraoperative Paragastric Block on Visceral Pain and Postoperative Nausea and Vomiting After Sleeve Gastrectomy: A Randomized Controlled Trial","BLOCK-SG","Inclusion Criteria\n\n* Patients aged between 18 and 65 years.\n* Candidates scheduled for elective LSG.\n* American Society of Anesthesiologists (ASA) physical status classification I-III.\n* Ability to provide written informed consent and willingness to comply with study procedures.\n\nExclusion Criteria\n\n* History of prior upper abdominal surgery.\n* Known psychiatric or neurological disorders that could interfere with pain assessment or postoperative care.\n* History of opioid dependency or chronic opioid use.\n* Allergy or hypersensitivity to local anesthetics or any of the medications used in the study protocol (e.g., paracetamol, dexketoprofen, ondansetron, tramadol, metoclopramide).\n* Severe hepatic, renal, or cardiac dysfunction (e.g., cirrhosis, end-stage renal disease, heart failure).\n* Pregnancy or breastfeeding.\n* Concomitant surgery (e.g., cholecystectomy, hiatal hernia repair, or abdominal wall repair).\n* Known bleeding disorders or coagulopathy (e.g., INR \\>1.5, platelet count \\\u003C50,000\u002Fmm³, or ongoing anticoagulant therapy)",{"count":350,"type":20},200,[56],"This single-center, prospective, randomized, double-blind controlled trial aims to evaluate the effects of intraoperative paragastric block (PGBLOCK) on early postoperative visceral pain, postoperative nausea and vomiting (PONV), and analgesic requirements in patients undergoing laparoscopic sleeve gastrectomy (LSG). Despite advancements in multimodal analgesia protocols, visceral pain remains a significant postoperative concern following LSG, contributing to increased opioid use and delayed recovery. Paragastric block is a novel technique targeting autonomic neural pathways-such as branches of the celiac ganglia and vagal nerves-through precise intraoperative injection of local anesthetics near the stomach.\n\nA total of 180 patients scheduled for elective LSG will be randomized in a 1:1 ratio to receive either paragastric block with 20 mL of 0.5% bupivacaine or a sham block with 20 mL of isotonic saline. Injections will be administered at six predefined anatomical sites under laparoscopic guidance after gastric resection. The surgical technique, anesthetic protocol, and postoperative care will be standardized for all participants. Both patients and clinical personnel involved in care and outcome assessment will remain blinded to group assignment.\n\nThe primary outcome is the assessment of postoperative visceral pain using Visual Analog Scale (VAS) scores at 0 and 2 hours postoperatively. Secondary outcomes include PONV severity grading, mobilization status, total analgesic consumption (pethidine + tramadol), and need for rescue antiemetics within the first 24 hours post-surgery. Exclusion criteria include history of upper abdominal surgery, chronic opioid use, pregnancy, severe systemic disease, or allergy to medications used in the protocol.\n\nThis study is expected to provide high-quality evidence regarding the efficacy of paragastric block in improving early postoperative recovery and reducing opioid reliance after LSG.",[26,354],"Postoperative Pain After Laparoscopic Sleeve Gastrectomy",[356,198,357,358,359],"postoperative pain","VAS","sleeve gastrectomy","paragastric block","2025-12-10",{"date":207,"type":36},{"date":363,"type":36},"2025-10-01",{"date":365,"type":20},"2026-01-20",{"name":367,"class":368},"Umraniye Education and Research Hospital","OTHER_GOV",{"id":370,"slug":371,"hasResults":11,"nctId":372,"briefTitle":373,"officialTitle":374,"acronym":4,"eligibilityCriteria":375,"healthyVolunteers":11,"sex":135,"minAge":17,"maxAge":165,"enrollmentInfo":376,"targetDuration":4,"studyType":21,"phases":378,"briefSummary":379,"conditions":380,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":381,"lastUpdatePostDateStruct":382,"startDateStruct":384,"completionDateStruct":386,"leadSponsor":388,"locationsCount":44},"100613788","effects-of-tavns-combined-with-dexmedetomidine-on-povn-100613788","NCT07271147","Effects of taVNS Combined With Dexmedetomidine on POVN","The Effect of Dexmedetomidine Combined With Percutaneous Auricular Vagus Nerve Stimulation on Postoperative Nausea and Vomiting in Female Laparoscopic Patients: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Women aged 18 to 65;\n* Elective laparoscopic surgery under general anesthesia;\n* Classified as American Society of Anesthesiologists (ASA) physical status I to II;\n* Capable of understanding the study procedures and various assessment scales and able to effectively communicate with the researchers;\n* Willing to participate in the study and provide written informed consent.\n\nExclusion Criteria:\n\n* Patients with ASA anesthesia classification ≥ III;\n* Poorly controlled hypertension, atrioventricular block ≥ second degree, obesity (BMI \\> 30 kg\u002Fm²);\n* Pregnant or breastfeeding;\n* Known allergy to drugs used in the study protocol, history of traumatic brain injury, history of gastrointestinal surgery;\n* Liver or kidney dysfunction (liver enzymes or creatinine ≥ 1.5 times the normal value), alcoholism or drug abuse, mental illness, use of antiemetics, opioids, psychoactive drugs, or corticosteroids within 24 hours before surgery;\n* Patients with implanted stimulators (such as pacemakers, implantable vagus nerve stimulators, deep brain stimulators, spinal cord stimulators, etc.), cochlear implants, or metal implants (except in dental cases);\n* Skin lesions or dermatological diseases at the site of electrical stimulation;\n* Preoperative heart rate \\\u003C 50 bpm or the presence of sinoatrial node disease or second-degree or higher atrioventricular block;\n* Patients unable to cooperate with assessments;\n* Patients participating in other clinical trials.",{"count":377,"type":20},176,[56],"To explore the effects and possible mechanisms of dexmedetomidine combined with taVNS on the incidence of postoperative nausea and vomiting in female patients undergoing laparoscopic surgery",[26],"2025-12-07",{"date":383,"type":36},"2025-12-09",{"date":385,"type":36},"2025-11-07",{"date":387,"type":20},"2026-12-01",{"name":389,"class":43},"Affiliated Hospital of Nantong University",{"id":391,"slug":392,"hasResults":11,"nctId":393,"briefTitle":394,"officialTitle":395,"acronym":4,"eligibilityCriteria":396,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":165,"enrollmentInfo":397,"targetDuration":4,"studyType":21,"phases":399,"briefSummary":400,"conditions":401,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":404,"lastUpdatePostDateStruct":405,"startDateStruct":407,"completionDateStruct":409,"leadSponsor":411,"locationsCount":44},"100592744","dexamethasone-palmitate-for-ponv-after-open-surgery-100592744","NCT06997419","Dexamethasone Palmitate for PONV After Open Surgery","Intravenous Dexamethasone Palmitate for Prophylaxis of Postoperative Nausea and Vomiting After Open Surgery","Inclusion Criteria:\n\n* Aged 18 to 65 years;\n* Providing written informed consent;\n* Perform elective open surgery (Spinal surgery, open chest surgery, open abdominal surgery) undergoing general anesthesia.\n\nExclusion Criteria:\n\n* Known to be allergic to dexamethasone;\n* Any systemic glucocorticoids within 3 months before trial entry;\n* History of severe heart disease, liver\u002Fkidney failure, or systemic rheumatic diseases (rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, et al);\n* Cognitive impairment or severe mental illness;\n* Uncontrolled diabetes or infectious diseases;\n* Pregnancy or breastfeeding.",{"count":398,"type":20},500,[56],"Dexamethasone is almost one of the most commonly used drugs for postoperative nausea and vomiting (PONV) prevention. However, PONV is still a complex problem to be solved; for example, even with preoperative dexamethasone administration, there are still some patients still experience PONV within 24 hours postoperatively. Compared to dexamethasone, dexamethasone palmitate has a long-lasting anti-inflammatory effect, 2-5 times that of traditional water-soluble dexamethasone, with fewer adverse effects. This trial aims to assess the effect and safety of preoperative dexamethasone palmitate on PONV after open surgery.",[26,402,403],"Dexamethasone Palmitate","Open Surgery","2025-09-21",{"date":406,"type":36},"2025-09-23",{"date":408,"type":36},"2025-07-01",{"date":410,"type":20},"2026-12-31",{"name":412,"class":43},"Beijing Tiantan Hospital",{"id":414,"slug":415,"hasResults":11,"nctId":416,"briefTitle":417,"officialTitle":418,"acronym":4,"eligibilityCriteria":419,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":165,"enrollmentInfo":420,"targetDuration":4,"studyType":21,"phases":421,"briefSummary":422,"conditions":423,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":404,"lastUpdatePostDateStruct":424,"startDateStruct":425,"completionDateStruct":427,"leadSponsor":429,"locationsCount":44},"100592030","dexamethasone-palmitate-for-ponv-after-craniotomy-100592030","NCT06988124","Dexamethasone Palmitate for PONV After Craniotomy","Intravenous Dexamethasone Palmitate for Prophylaxis of Postoperative Nausea and Vomiting After Craniotomy","Inclusion Criteria:\n\n* Aged 18 to 65 years;\n* Providing written informed consent;\n* Perform elective craniotomy undergoing general anesthesia.\n\nExclusion Criteria:\n\n* Known to be allergic to dexamethasone;\n* Any systemic glucocorticoids within 3 months before trial entry;\n* History of severe heart disease, liver\u002Fkidney failure, or systemic rheumatic diseases (rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, et al);\n* Cognitive impairment or severe mental illness;\n* Uncontrolled diabetes or infectious diseases;\n* Pregnancy or breastfeeding.",{"count":398,"type":20},[56],"Dexamethasone is almost one of the most commonly used drugs for postoperative nausea and vomiting (PONV) prevention. However, PONV is still a complex problem to be solved; for example, even with preoperative dexamethasone administration, there are still some patients undergoing craniotomy still experience PONV within 24 hours postoperatively. Compared to dexamethasone, dexamethasone palmitate has a long-lasting anti-inflammatory effect, 2-5 times that of traditional water-soluble dexamethasone, with fewer adverse effects. This trial aims to assess the effect and safety of preoperative dexamethasone palmitate on PONV after craniotomy.",[26],{"date":406,"type":36},{"date":426,"type":36},"2025-06-25",{"date":428,"type":20},"2027-06-01",{"name":412,"class":43},{"id":431,"slug":432,"hasResults":11,"nctId":433,"briefTitle":434,"officialTitle":434,"acronym":4,"eligibilityCriteria":435,"healthyVolunteers":436,"sex":135,"minAge":17,"maxAge":437,"enrollmentInfo":438,"targetDuration":4,"studyType":21,"phases":440,"briefSummary":442,"conditions":443,"keywords":444,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":445,"lastUpdatePostDateStruct":446,"startDateStruct":448,"completionDateStruct":450,"leadSponsor":451,"locationsCount":44},"100553585","phase-2-preoperative-use-of-pantoprazole-for-prevention-of-post-operative-nausea-and-vomiting-in-gynecologic-surgery-100553585","NCT06488001","Preoperative Use of Pantoprazole for Prevention of Post Operative Nausea and Vomiting in Gynecologic Surgery","Inclusion Criteria:\n\n* Undergoing elective gynecological surgery by either an open abdominal or minimally invasive approach (to include both endoscopic and vaginal). Procedure must be performed under general anesthesia.\n\nExclusion Criteria:\n\n* Pregnant,\n* Patients with gastrointestinal disease requiring ongoing medical management.\n* Prior gastrointestinal surgery with the exception of diagnostic procedures, appendectomy and cholecystectomy.\n* Patients with a history of H2 receptor blocker use, proton pump inhibitor use or other GERD specific therapy within 30 days of surgery.\n* Any patient identified by their surgical care team as having a history of PONV warranting additional perioperative prophylaxis.\n* Known r suspected malignancy\n* Lactose intolerance",true,"79 Years",{"count":439,"type":20},132,[441],"PHASE2","The goal of this clinical trial is to see if pantoprazole (a proton pump inhibitor used for acid reflux\u002Fheart burn) can reduce nausea and vomiting after gynecologic surgery in women between the ages of 18 and 79.\n\nResearchers will compare a placebo to the active medication.\n\nParticipants will be asked to take three pills around their surgery, two taken before and one taken the night after.",[26],[28,30],"2025-05-16",{"date":447,"type":36},"2025-05-21",{"date":449,"type":36},"2022-08-26",{"date":125,"type":20},{"name":452,"class":453},"United States Naval Medical Center, Portsmouth","FED",{"id":455,"slug":456,"hasResults":11,"nctId":457,"briefTitle":458,"officialTitle":459,"acronym":28,"eligibilityCriteria":460,"healthyVolunteers":436,"sex":16,"minAge":461,"maxAge":4,"enrollmentInfo":462,"targetDuration":4,"studyType":21,"phases":464,"briefSummary":465,"conditions":466,"keywords":468,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":472,"lastUpdatePostDateStruct":473,"startDateStruct":475,"completionDateStruct":477,"leadSponsor":479,"locationsCount":481},"100557651","phase-4-a-comparison-between-palonosetron-versus-granisetron-as-ponv-prophylaxis-in-scoliotic-patients-undergoing-spine-surgery-100557651","NCT06540885","A Comparison Between Palonosetron Versus Granisetron as PONV Prophylaxis in Scoliotic Patients Undergoing Spine Surgery","A Comparison Between Palonosetron Versus Granisetron As Postoperative Nausea and Vomiting Prophylaxis In Idiopathic Scoliosis Surgery: A Randomized Control Trial","Inclusion Criteria:\n\n* Age: 10 years and above\n* American Society of Anesthesiologists (ASA) class I-II\n\nExclusion Criteria:\n\n* Active smoker\n* Obesity with body mass index (BMI) of 34 and above\n* Body weight of less than 30kg\n* History of gastro-esophageal reflux disease (GERD)\u002F other gastrointestinal diseases associated with vomiting\n* History of motion sickness\n* History of allergy to 5-HT3 (serotonin) receptor antagonists or dexamethasone\n* History of nausea or vomiting withing 24 hours before surgery\n* History of administration of antiemetics\u002F steroids\u002F psychoactive medications within 24 hours before the surgery\n* History of cardiac arrhythmias\n* Prolonged QT (QTc is prolonged if \\> 430ms in men or \\>450ms in women)","10 Years",{"count":463,"type":20},74,[23],"The aim of this clinical trial is to compare the effectiveness of two Serotonin (5- HT3) receptor antagonist, palonosetron and granisetron, administered along with dexamethasone as a preventive measure against early and delayed postoperative nausea and vomiting (PONV) in adult and adolescent patients with idiopathic scoliosis (IS) undergoing posterior spinal fusion (PSF) surgery under total intravenous anesthesia (TIVA).\n\nThe main questions the study aims to answer are:\n\nHow effective is palonosetron compared to granisetron, when both combined with dexamethasone, in preventing PONV after scoliosis surgery? Are there any differences in the need for rescue antiemetics, occurrence of adverse effects related to the study drugs, and patient satisfaction between the two treatment groups? Participants in the study will be randomly assigned to receive either palonosetron or granisetron in addition to dexamethasone as part of their anesthesia and antiemetic regimen. The incidence and\u002F or severity of nausea, vomiting and retching will be assessed at 1 hour, 4 hours, 12 hours, 24 hours and 48 hours after surgery.",[26,467],"Scoliosis",[469,470,471],"Antiemetics","Granisetron","Palonosetron","2025-04-22",{"date":474,"type":36},"2025-04-25",{"date":476,"type":36},"2025-01-06",{"date":478,"type":20},"2026-09-30",{"name":480,"class":43},"University of Malaya",2,{"id":483,"slug":484,"hasResults":11,"nctId":485,"briefTitle":486,"officialTitle":487,"acronym":4,"eligibilityCriteria":488,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":165,"enrollmentInfo":489,"targetDuration":4,"studyType":21,"phases":490,"briefSummary":491,"conditions":492,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":493,"lastUpdatePostDateStruct":494,"startDateStruct":496,"completionDateStruct":498,"leadSponsor":499,"locationsCount":44},"100520734","effect-of-lavender-aromatherapy-on-post-operative-nausea-and-vomiting-among-laparotomy-patients-100520734","NCT06060418","Effect of Lavender Aromatherapy on Post-Operative Nausea and Vomiting Among Laparotomy Patients","Effect of Lavender Aromatherapy on Post-Operative Nausea and Vomiting Among Laparotomy Patients At DHQ Sheikhupura Punjab, Pakistan","Inclusion Criteria:\n\nThose patients: -\n\n* with 18 -65 years\n* both Male and Female\n* who received general anesthesia for surgery\n* who experience nausea and vomiting within 24hr after surgery\n* who hemodynamically stable\n\nExclusion Criteria:\n\nThose patients\n\n* • who move to ICU after the Procedure\n\n  * with history of substance addiction\n  * having history of pre-op nausea and vomiting\n  * with history of motion sickness\n  * who start Oral or Naso Gastric Feed after surgery\n  * having history of Lung disease, ant type of allergy or infection\n  * who need laparotomy reversal short after the procedure\n  * Who received antiemetic before surgery\n  * who went to any type of complication during the procedure not included in this study.",{"count":167,"type":20},[56],"Post-operative nausea and vomiting are critical problems that occur commonly after the administration of general anesthesia, which can lead to serious health complications such as hemorrhage, electrolyte imbalance and ultimate shock. To prevent these complications, antiemetic drugs are often administered, but they can cause side effects as well as increased healthcare costs. As concerns regarding the side effects of antiemetic drugs have grown, there has been an increased interest in using non-pharmacologic interventions, such as aromatherapy, as an alternative approach to preventing post-operative nausea and vomiting. It involves the therapeutic use of essential oils, and lavender essential oil, in particular, is commonly used for various digestive problems including nausea, and vomiting. Therefore, a key question for a health care professional is how to prevent post-operative nausea and vomiting in best possible manner? To address this question, a study will be conducted in District Head Quarter Sheikhupura, aiming to evaluate the effectiveness of lavender essential oil aromatherapy in reducing post-operative nausea and vomiting among patients admitted for laparotomy under general anesthesia. This study will be a Randomized control trial with the study population consisting of admitted patients after laparotomy under general anesthesia. The sample size will be 70, who will be divided into two groups, each consisting of 35 participants. A convenience sampling technique will be employed for the recruitment of participants. After that, the participants will be randomized into control and intervention groups by computer-generated table numbers in accordance with the inclusion criteria that is, 18-65 age, both genders, laparotomy under general anesthesia, clinically stable, and susceptive to post-op nausea and vomiting within 24hrs following the surgery. whereas, the patients with respiratory diseases, allergies, infections, reversal laparotomy within short duration, having any kind of addiction, those who move to the intensive care unit, those with a history of motion sickness, history of pre-op nausea and vomiting and those who start oral or NG feed before 24hrs will not be part of this study. The data will be analyzed by using Statistical Package for Social Sciences version 22.",[26],"2024-09-23",{"date":495,"type":36},"2024-09-25",{"date":497,"type":20},"2024-10",{"date":497,"type":20},{"name":500,"class":43},"University of Health Sciences Lahore",{"id":502,"slug":503,"hasResults":11,"nctId":504,"briefTitle":505,"officialTitle":506,"acronym":4,"eligibilityCriteria":507,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":508,"targetDuration":4,"studyType":21,"phases":510,"briefSummary":511,"conditions":512,"keywords":515,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":519,"lastUpdatePostDateStruct":520,"startDateStruct":522,"completionDateStruct":524,"leadSponsor":526,"locationsCount":44},"100501079","phase-4-pregabalin-in-the-obese-patients-undergoing-laparoscopic-sleeve-gastrectomy-lsg-100501079","NCT05804591","Pregabalin in the Obese Patients Undergoing Laparoscopic Sleeve Gastrectomy (LSG).","The Effect of Preemptive Oral Pregabalin As an Element of Multimodal Analgesia in Patients Undergoing Laparoscopic Sleeve Gastrectomy. a Randomized, Prospective, Double Blind Study.","Inclusion Criteria:\n\n* Sleeve gastrectomy in patients with BMI \\> 40 or \\>35 with comorbidities\n* Written informed consent\n\nExclusion Criteria:\n\n* Patient's refusal\n* Known allergies to study medication\n* Inability to comprehend or participate In pain scoring scale\n* Inability to use intravenous patient controlled analgesia\n* Changes of operation extent during procedure\n* Revisional operations\n* End stage organ failure",{"count":509,"type":20},90,[23],"The aim of this clinical trial is to assess preemptive oral pregabalin administration in the obese patients undergoing laparoscopic sleeve gastrectomy. The main aims of the study are to evaluate postoperative pain treatment and effect on the intraoperative hemodynamical stability.\n\nThe participants will be divided into 2 groups: with or without preemptive pregabalin administration.",[513,171,26,514],"Obesity","Opioid Use",[516,513,517,518],"Laparoscopic sleeve gastrectomy","Pregabalin","Multimodal analgesia","2024-09-12",{"date":521,"type":36},"2024-09-19",{"date":523,"type":36},"2023-04-24",{"date":525,"type":20},"2025-08-01",{"name":527,"class":43},"Medical University of Warsaw"]